Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Arovella Therapeutics Limited ( (AU:ALA) ) has provided an announcement.
Arovella Therapeutics Limited announced the issuance of 936,303 ordinary shares without disclosure under Part 6D.2 of the Corporations Act. The company has complied with relevant provisions of the Corporations Act and confirmed no excluded information needs to be disclosed. This issuance is part of Arovella’s strategic efforts to strengthen its financial position and support its ongoing development of innovative cancer therapies.
More about Arovella Therapeutics Limited
Arovella Therapeutics Ltd is a biotechnology company focused on developing invariant natural killer T (iNKT) cell therapy to treat blood cancers and solid tumors. Their lead product, ALA-101, utilizes CAR19-iNKT cells targeting CD19, an antigen found on various cancer types. The company is also expanding into solid tumor treatment with CLDN18.2-targeting technology and incorporating IL-12-TM technology into its programs.
Average Trading Volume: 1,875,347
Technical Sentiment Signal: Sell
Current Market Cap: A$124.8M
For a thorough assessment of ALA stock, go to TipRanks’ Stock Analysis page.